Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530801 | 1.00 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTLMNAHPGD | |
| SCHEMBL14448355 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTLMNAHPGD | |
| SCHEMBL5531048 | 0.79 | ALDH1A1 (0.64) | ALDH1A1MAPTLMNAHPGDHTT | |
| SCHEMBL5531050 | 0.79 | ALDH1A1 (0.64) | ALDH1A1MAPTLMNAHPGDHTT | |
| SCHEMBL5530804 | 0.78 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPTLMNAHPGD | |
| SCHEMBL4006313 | 0.76 | THRB (0.77) | ALDH1A1KDM4EMAPTLMNASMN1; SMN2 | |
| SCHEMBL5527789 | 0.75 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTLMNAHPGD | |
| SCHEMBL5527787 | 0.75 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTLMNAHPGD | |
| SCHEMBL5524860 | 0.74 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL5524866 | 0.74 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203140-A1 | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-30 | — | — | US | claimed |
| WO-2007095050-A2 | N-HYDROXYGUANIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2007-08-23 | — | — | WO | claimed |
| US-20070203140-A1 | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203140-A1 | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, HNMT | ALDH1A1 764/4885KDM4E 810/4885MAPT 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.